DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20164153

The emerging role of MD Pharmacology postgraduate in pharmaceutical industry

Pratishtha Banga Chaudhari

Abstract


Patient-benefit is a shared goal of the pharmaceutical company and the treating doctor. At the same time, the pharmaceutical company- in order to recur its R and D costs has to balance patient centricity with making profits. Consequently, the commercial benefits from prescription of a product and education about optimal use of product both become the responsibilities of same organization. This often leads to allegations of bias by the regulators. We are in an era where regulatory bodies closely monitor the promotional method of drugs, the validity of information being communicated, to what audience the information is shared, who all can share the information from the company's end. Thus the pharmaceutical companies split the two functions and allocated a set of medical professionals for handling the scientific interactions. The larger objective of the pharmaceutical company is optimum product utilization via educating the potential prescribers about efficacy and safety data of the product, and not just generates sales. Medical affairs serves as a link of pharmaceutical company who intends to develop a peer-to-peer relationship with HCP, through-out the life-cycle of product and provides a scientific interface of the prescribing clinicians and the pharmaceutical industry. Medical affairs role encompasses scientific, informational, communications and interpersonal activities. This article emphasizes on the evolving role of medical affairs in the pharmaceutical industry so as to provide a clear idea to the pharmacology post graduates.


Keywords


Career, Medical affairs, Pharmacology, Pharmaceutical industry, Regulatory

Full Text:

PDF

References


Taylor D. The Pharmaceutical Industry and the Future of Drug Development, in Pharmaceuticals in the Environment, 2015, pp. 1-33.

Angell M. The Truth About the Drug Companies, Random House, New York, 2004.

Law J. Big Pharma, Constable, London, 2006

Roig B. Pharmaceuticals in the Environment, Current Knowledge and Needs Assessment to Reduce Pressure and Impact, ed. Benoit Roig, IWA Publishing, 2010.

Shivprakash. Pharmacology: taking it forward. Indian J Pharmacol. 2007;39:3-4.

Ghosh RK, Ghosh SM, Datta S. Training of postgraduate pharmacologists in India - The need for alignment with the emerging roles in the pharmaceutical industry. J Postgrad Med. 2010;56:168-9.

Medical curriculum brochure, JIPMER, MD Pharmacology, 2008-2009.

Iain C, Henderson R. 1997. Public-Private Interaction and the Productivity of Pharmaceutical Research. National Bureau of Economic Research working paper 6018.

Michael McGinnis J, Olsen L, Bothner K. Learning What Works Best: The Nation's Need for Evidence on Comparative Effectiveness in Health Care: an issue overview IOM roundtable on evidence-based medicine. September 2007.

Annetine G, Rosenberg N. Capturing the Unexpected Benefits of Medical Research.New England Journal of Medicine. 1998;339(10):693-7.

Eliades G, Retterath M, Hueltenschmidt N, Singh K. Healthcare 2020. Retrieved from http://www.bain.com/Images/BAIN_BERIEF_Healthcare_2020.pdf. 2021.

Porter ME, Lee TH. Harvard Business Review, Healthcare 2020. Strategy. The Strategy That Will Fix Health Care. October 2013.

Charles I, Williams JC. Measuring the Social Return to R and D. Quarterly Journal of Economics. 1998;113(4):1119-35.

MSLS. Availbale from: http://blog.themsls.org/2014/11/what-you-dont-know-about-communication-can-hurt-you/ accessed on 19.5.2015.